New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder

@article{Patrick2005NewMF,
  title={New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder},
  author={K. Patrick and M. Gonzalez and A. Straughn and J. Markowitz},
  journal={Expert Opinion on Drug Delivery},
  year={2005},
  volume={2},
  pages={121 - 143}
}
dl-Methylphenidate (MPH) remains the most widely used pharmacological agent in the treatment of attention-deficit/hyperactivity disorder (ADHD). The predominantly dopaminergic mechanism of the psychostimulant actions has become more clearly defined. Neuroimaging and genetic studies are revealing the underlying neuropathology in ADHD. Novel extended-release (ER) MPH formulations now offer drug delivery options to overcome both the short-term actions of immediate-release (IR) MPH and the acute… Expand
48 Citations
Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate
  • R. Maldonado
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2013
  • 32
  • Highly Influenced
Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder
  • 6
Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
  • D. Sugrue, R. Bogner, M. Ehret
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2014
  • 20
Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability.
  • 10
  • PDF
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations
  • 5
  • Highly Influenced
Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder.
  • 39
  • Highly Influenced
  • PDF
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?
  • 57
New Formulations of Stimulants: An Update for Clinicians.
  • 7
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 225 REFERENCES
Mechanism of action of methylphenidate: Insights from PET imaging studies
  • 289
Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.
  • 399
  • PDF
Neurobehavioral effects of racemic threo-methylphenidate and its d and l enantiomers in rats
  • 34
Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-Analysis
  • 81
Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD
  • 163
...
1
2
3
4
5
...